| abstract |
Disclosed are a fused ring-structured benzamide compound and an application thereof. Pharmacological experiments show that the compound of the present invention provides great histone deacetylase 1 (HDAC1) inhibitory activity, weak inhibition against normal cells, reduced toxicity, should provide further reduced toxic side effects when applied as an antineoplastic medicament, and further facilitates use as the antineoplastic medicament. The present invention provides great efficacy in the treatment of diseases induced by abnormal gene expression, such as: tumors, endocrine disorders, immune system diseases, genetic diseases, and neurological diseases. The fused ring-structured benzamide compound is a compound as represented by formula (V) or a pharmaceutically acceptable salt thereof. |